168
Participants
Start Date
May 20, 2020
Primary Completion Date
July 29, 2020
Study Completion Date
August 4, 2020
Favipiravir
TL-FVP-t will be administered orally
Standard of care (SOC)
SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19
standard concomitant therapy
Standard of care according to MoH of Russian Federation recomendation for COVID-19
"Medical center LLC Neuroprofi", Korolyov
"Federal budgetary institution of science Central Research Institute of Epidemiology of Russian Federal Supervision Service for Consumer Rights Protection and People's Welfare", Moscow
"Medical centers JSC Medsi Group of Companies", Moscow
"State budgetary institution of health care of the city of Moscow City Clinical Hospital №52 of the Moscow City Healthcare Department", Moscow
"State budgetary institution of health care of the city of Moscow City Clinical Hospital №67 n.a. LA Vorokhobova of the Moscow City Healthcare Department", Moscow
"State budgetary institution of health care of the city of Moscow Infectious Diseases Clinical Hospital №1 of the Moscow City Healthcare Department", Moscow
"Medical center LLC Medical Center Eco-safety", Saint Petersburg
"St. Petersburg State Budgetary Healthcare Institution City Hospital No. 40 of the Kurortny District", Saint Petersburg
"Budgetary healthcare institution of the Voronezh region Voronezh Regional Clinical Hospital No. 1", Voronezh
"State Budgetary Healthcare Institution of the Moscow Region Zhukovskaya City Clinical Hospital.", Zhukovskiy
Lead Sponsor
R-Pharm
INDUSTRY